Mourabit Halima, Author at MediaMedic

Filipa Fonseca Challenges Traditional EGJ Cancer Classification with Innovative Approach at ISDE 2024

By Mourabit Halima 2024.10.23

From September 22nd to 24th, 2024, the 20th International Society for Diseases of the Esophagus (ISDE) conference was grandly held in Edinburgh, Scotland. Dr. Filipa Fonseca from the Lisbon Oncology Research Center presented a study on the modified Siewert classification for adenocarcinoma of the esophagogastric junction (EGJ) at the Late-Breaking Oral Abstract session (Abstract No.: LB-OA02.07), which sparked extensive discussion and interest. Oncology Frontier conducted an exclusive interview with Prof. Fonseca at the conference venue regarding this classification method.

ISDE 2024 | Groundbreaking: Prehabilitation Transforms Borderline Resectable Esophageal Cancer Patients into Surgical Candidates

By Mourabit Halima 2024.10.23

The 20th International Society for Diseases of the Esophagus (ISDE) conference took place in Edinburgh, Scotland, from September 22nd to 24th, 2024. At the conference, a study by Dr. Krishna Moorthy from the Royal College of Surgeons in the UK on whether prehabilitation can increase the surgical opportunities for esophageal cancer patients was selected for presentation (Abstract No.: S19.02). Oncology Frontier conducted an exclusive interview with Professor Moorthy at the conference venue about this research. The interview content has been organized and the relevant study abstract is attached for reference.

Integrative Medicine Shines at CACA: Dr. Liu Hong Outlines New Horizons in Esophageal Cancer Treatment

By Mourabit Halima 2024.10.23

From September 26 to 28, 2024, the China Anti-Cancer Association (CACA) and the CACA Integrative Esophageal Cancer Committee hosted the 2024 CACA Integrative Esophageal Cancer Academic Conference in Hefei. The conference, under the theme “Winning in Integration for Cancer Prevention and Treatment,” gathered the latest research developments and clinical experiences from experts in esophageal cancer worldwide. During the event, Oncology Frontier had the opportunity to interview Dr. Liu Hong from The First Affiliated Hospital of Air Force Medical University (Xijing Hospital). In this interview, Professor Hong delves into the trends of integrative treatment, individualized care, and the importance of comprehensive patient management. Below is the full transcript of the interview for our readers.

Breaking New Ground in T-Cell Lymphoma Treatment: Insights from Dr. Swaminathan P iyer Iyer and Dr. Lihua Qiu

By Mourabit Halima 2024.10.22

In a recent discussion, Dr. Swaminathan Iyer from MD Anderson Cancer Center and Dr. Lihua Qiu highlighted the evolving landscape of peripheral T-cell lymphoma (PTCL) treatment. They emphasized the importance of cross-border collaboration to tackle the complexities of PTCL and the promising advancements in therapies such as PI3K inhibitors, EZH2 inhibitors, and JAK1 inhibitors. With a focus on precision medicine, Dr. Iyer and Dr. Qiu underscored the significance of personalized approaches, new targeted therapies, and CAR-T development for improved patient outcomes. Discover how global collaborations are driving innovation in T-cell lymphoma care!

Breaking Ground in STS Treatment: Dr. Yuhong Zhou Champions Anti-Angiogenic TKIs at CSCO 2024

By Mourabit Halima 2024.10.22

Soft tissue sarcoma (STS) is a highly heterogeneous group of tumors with complex pathology, and the benefits of first-line chemotherapy, primarily anthracycline-based, are limited. As a result, patient prognosis remains poor overall. In recent years, anti-angiogenic tyrosine kinase inhibitors (TKIs) have emerged as a promising option for second- and later-line treatments, with potential for expansion into the first-line setting. At the 2024 CSCO conference, Dr. Yuhong Zhou from Zhongshan Hospital, Fudan University, delivered a detailed presentation on the latest research in anti-angiogenic TKIs for STS. In an exclusive interview with Oncology Frontier, she also shared insights into the advancements in diagnosis and treatment in this field.

ISDE 2024 | Revolutionizing Esophageal Cancer Treatment: FLOT Regimen Emerges as a Frontrunner in ISDE 2024

By Mourabit Halima 2024.10.22

In a special interview at the 20th International Society for Diseases of the Esophagus (ISDE) conference, Dr. Jens Hoeppner from Bielefeld University in Germany shared his insights on the FLOT regimen's clinical benefits over the CROSS regimen in the treatment of locally advanced resectable esophageal adenocarcinoma. He also discussed the potential integration of immunotherapy and the 'watch and wait' strategy in future treatments.

Advancements in Targeted Therapies for Mycosis Fungoides and Sézary Syndrome: Dr. Lanfang Li and Professor Zhuang Weiyun Share Key Insights

By Mourabit Halima 2024.10.22

In a recent interview, Dr. Lanfang Li and Professor Zhuang Weiyun from the University of California, San Francisco discussed breakthroughs in treating Mycosis Fungoides (MF) and Sézary Syndrome (SS), focusing on the efficacy of brentuximab vedotin and mogamulizumab. They highlighted the importance of targeting different disease compartments and leveraging new drugs to improve patient outcomes. With advancements in targeted therapies and an emphasis on early diagnosis, the experts emphasized the need for multidisciplinary collaboration to better manage these rare but challenging conditions.

Exploring Evolving Strategies for HR-Positive Breast Cancer with Dr. Virginia Kaklamani

By Mourabit Halima 2024.10.22

In a recent interview, Dr. Virginia Kaklamani discussed the rapidly advancing landscape of hormone receptor-positive breast cancer treatments. With the emergence of novel medications like CDK4-6 inhibitors, oral SERDs, and PI3K/AKT pathway inhibitors, she emphasized the need for NGS testing to guide treatment decisions. Dr. Kaklamani highlighted the unique efficacy and safety profiles of alpelisib, inovolacib, and capivacertib, and provided insights on selecting the most suitable therapy based on specific genetic mutations.

CSCO 2024 | Dr. Yilong Wu: How to Make Targeted Therapy Decisions for NSCLC Patients with EGFR Mutations

By Mourabit Halima 2024.10.21

The 27th National Conference on Clinical Oncology and the 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was held from September 25 to 29, 2024, in Xiamen. During the conference, several forums on lung cancer covered cutting-edge research and developments in the field. During the event, Oncology Frontier invited Dr. Yilong Wu from Guangdong Provincial People’s Hospital to share his insights on making targeted therapy decisions for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

CSCO 2024丨Dr. Jun Ma Reflects on CSCO’s Glorious Journey: China’s Rise in Oncology on the Global Stage

By Mourabit Halima 2024.10.21

From September 25-29, 2024, the "27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting," hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference will showcase major research advancements and developments in the field both domestically and internationally. Over the past 20 years, CSCO has continuously led the development of clinical oncology in China, with many experts deeply involved in its growth, advancing their careers through this platform. Hematology Frontier has launched a special "Growing with CSCO" series in response to CSCO's call, inviting Chinese scholars to revisit past stories. In this issue, we have invited Dr. Jun Ma, Chairman of the Supervisory Board of CSCO and Director of the Harbin Institute of Hematology and Oncology, to share his touching stories of "growing with CSCO."